TREATMENT OF DISEASES, DISORDERS OR CONDITIONS OF THE LUNG USING PLACENTAL CELLS

• US 20100143312A1
• Filed: 11/23/2009
• Published: 06/10/2010
• Est. Priority Date: 11/21/2008
• Status: Abandoned Application

• Current Assignee: Celularity, Inc.
• Original Assignee: Celularity, Inc.
• Inventors: HARIRI, Robert J., Faleck, Herbert, Zeitlin, Andrew
• Application Number:
  US12/624,359
• Publication Number:
  US 20100143312A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Provided herein are compositions and methods of treatment of individuals having a disease, disorder or condition of the lung, comprising administering a therapeutically-effective amount of placental cells, e.g., placental stem cells.

Claims

1. A method of treating an individual having a disease, disorder or condition of the lung, comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition.

2. The method of claim 1, comprising detecting said improvement by one or more of spirometry, peak flow meter, detection of CO₂ levels in the blood, radiography, CT scanning, magnetic resonance imaging, bronchoscopy, or broncheolar lavage.

3. The method of claim 1, wherein said disease, disorder or condition is associated with or caused by an immune response.

4. The method of claim 3, wherein said disease, disorder or condition is an autoimmune disease.

5. The method of claim 4, wherein said autoimmune disease is rheumatoid arthritis, scleroderma, inflammatory bowel disease, or systemic lupus erythematosus.

6. The method of claim 3, wherein said disease, disorder or condition is graft-versus-host disease.

7. The method of claim 1, wherein said disease, disorder or condition is an interstitial lung disease.

8. The method of claim 7, wherein said interstitial lung disease is interstitial pulmonary fibrosis.

9. The method of claim 1, wherein said disease, disorder or condition is an obstructive lung disease.

10. The method of claim 9, wherein said obstructive lung disease is asthma, bronchitis, acute respiratory distress syndrome or chronic obstructive pulmonary disease.

11. The method of claim 1, wherein said disease, disorder or condition is an acute lung injury.

12. The method of claim 11, wherein said acute lung injury is caused by a chemical burn, smoke inhalation, or exposure to a toxic substance.

13. The method of claim 1, wherein said disease, disorder or condition is a lung injury caused by a neoplastic or paraneoplastic disease, pneumonia, or cystic fibrosis.

14. The method of claim 13, wherein said administration results in a forced expiratory volume in 1 second (FEV₁) to forced vital capacity (FVC) ratio of above 0.7.

15. The method of claim 1, wherein said placental stem cells are CD10⁺, CD34⁻

, CD105⁺, as detected by flow cytometry.

16. The method of claim 15, wherein said cells are CD200⁺, as detected by flow cytometry.

17. The method of claim 16, wherein said cells are CD90⁺ and CD45⁻

, as detected by flow cytometry.

18. The method of claim 17, wherein said cells are CD44⁺, as detected by flow cytometry.

19. The method of claim 17, wherein said cells are CD80⁻

and CD86⁻

, as detected by flow cytometry.

20. The method of claim 15, wherein said cells are one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺, as detected by flow cytometry.

21. The method of claim 15, wherein said cells are at least one of CD200⁺, CD44⁺, CD45⁻

, CD90⁺, CD117⁻

, CD133⁻

, KDR⁻

, CD80⁻

, CD86⁻

, HLA-ABC⁺, HLA-DR⁻

, or PDL⁺